Stay updated with breaking news from Evidence Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medicare Part B will provide coverage for new amyloid-busting Alzheimer’s drugs as soon as the Food and Drug Administration grants traditional (full) approval, the Centers for Medicare & Medicaid Services announced Thursday morning. Coverage will require clinicians to participate in a patient data registry.
CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”
MOULTRIE, Ga. — Alzheimer’s disease and other dementias are devastating. On Jan. 6, the U.S. Food and Drug Administration approved a medication that offers hope to those with Alzheimer's.
On February 13-14, 2023, the Centers for Medicare & Medicaid Services (CMS) convened a virtual panel of the Medicare Evidence Development & Coverage…
The Centers for Medicare and Medicaid Services is not reconsidering the national coverage determination for Food and Drug Administration (FDA)-approved medications for Alzheimer's disease. The FDA-approved monoclonal antibodies are directed against amyloid, or the protein buildup, for the treatment of Alzheimer's disease. "We recognize that these medications are a unique, new